Four-Part Case Series: Bipolar Disorder with Mixed Features - Q&A Session 1
neuroscienceCME WebcastPremiere Date: Tuesday, June 20, 2017
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, June 20, 2018
|Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto
Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Bipolar disorder is a severe psychiatric disorder that is frequently associated with persistent symptoms and significant dysfunction. The symptoms of mania demand the most attention in bipolar disorder.
While there are numerous psychopharmacologic agents that are available for treatment of this illness, suboptimal response and significant adverse consequences limit their utility.1 New medications to treat bipolar disorder can offer clinicians more options and generally newer medications improve upon tolerability and side effect profile of previous antipsychotic agents. Evidence suggests that the symptoms of bipolar disorder are recurrent and can worsen over repeated relapses. The goal is to effective manage symptoms and prevent relapse.
In this CME Outfitters patient case and expert consult Q & A session, faculty will go in-depth with the case study answering your questions while offering evidence, guidelines, and quality measures for collaborative strategies to optimally care for patients with bipolar disorder.
Citrome L. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211-1220.
At the end of this CE activity, participants should be able to:
- Review the efficacy and safety profile of recent agents approved for the treatment of bipolar disorder.
- Implement a treatment plan that includes the latest treatment options and advancements in the management of bipolar disorder as an option.
Supported by an educational grant from Allergan.
Psychiatrists, pharmacists, and other members of the interprofessional team caring for individuals with bipolar disorder.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .75 contact hours (0.75 CEUs) Universal Activity Number:
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McIntyre has disclosed that he receives grant support from Allergan; AstraZeneca; Janssen Pharmaceuticals Inc.; Lundbeck; Otsuka; Pfizer Inc.; Purdue Pharma; and Shire. He serves on the advisory board for AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; PurduePharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited. He serves on the speakers bureau for AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; PurduePharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).